{
    "clinical_study": {
        "@rank": "144724", 
        "brief_summary": {
            "textblock": "Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As\n      tumors respond to treatment, preliminary data suggests that the blood volumes changes as\n      well. Investigators are therefore using DECT to test whether it can be used on radiation\n      treatment to rapidly assess response to treatment."
        }, 
        "brief_title": "Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer Stage III", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged greater than 18 years with a diagnosis of stage III non-small cell lung\n             cancer.\n\n          -  Planned treatment with either definitive chemoradiotherapy or preoperative\n             chemoradiotherapy followed by surgical resection.\n\n          -  PET-CT study within 4 weeks of next available DECT study.\n\n          -  Patients must have measurable primary and nodal disease, defined by at least one\n             lesion (primary and lymph node) greater than 1 cm.\n\n          -  Kidney function sufficient to tolerate iodine-based CT contrast.\n\n          -  No allergy to iodine-based contrast.\n\n          -  Ability to understand and the willingness to sign informed consent.\n\n        Exclusion Criteria:\n\n          -  Participants with a prior history of thoracic radiotherapy.\n\n          -  Participants may not be receiving any other study agents.\n\n          -  Inability to tolerate CT contrast\n\n          -  Pregnant women are excluded from this study because radiotherapy has the potential\n             for teratogenic or abortifacient effects. Because there is an unknown but potential\n             risk of adverse events in nursing infants secondary to treatment of the mother with\n             radiotherapy, breastfeeding should be discontinued if the mother is treated with\n             radiotherapy. These potential risks may also apply to other agents used in this\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with stage III lung cancer treated with chemoradiotherapy or chemoradiotherapy\n        followed by surgery"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02053285", 
            "org_study_id": "12051502-IRB01"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "contact": {
                "email": "david_sher@rush.edu", 
                "last_name": "David J Sher, MD, MPH", 
                "phone": "312-942-6817"
            }, 
            "contact_backup": {
                "email": "josephine_volgi@rush.edu", 
                "last_name": "Josephine Volgi, RN", 
                "phone": "312-563-2741"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60612"
                }, 
                "name": "Rush University Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This change in the maximum IRA will be compared with the change in the maximum standardized uptake value (SUV max) between baseline PET-CT and follow-up PET-CT at 3 months after treatment. For patients undergoing surgery, this change in the maximum IRA will be compared between patients who have a complete pathologic response, and those patients who do not.", 
            "measure": "Change in the tumor's maximum iodine related attenuation (IRA) from baseline to on-treatment DECT.", 
            "safety_issue": "No", 
            "time_frame": "0, 1, 3, 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053285"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Rush University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rush University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}